Assessing the effects of topical cannabidiol in patients with atopic dermatitis.

[1]  D. Rosmarin,et al.  A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor , 2019, Journal of the American Academy of Dermatology.

[2]  M. Gooderham,et al.  Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis , 2018, Journal of cutaneous medicine and surgery.

[3]  S. Elmariah.  Adjunctive Management of Itch in Atopic Dermatitis. , 2017, Dermatologic clinics.

[4]  K. Westlund,et al.  Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis , 2016, European journal of pain.

[5]  A. A. Ahmed,et al.  Molecular Genetic of Atopic dermatitis: An Update. , 2016, International journal of health sciences.

[6]  Bong-Woo Kim,et al.  Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model , 2016, Annals of dermatology.

[7]  S. Nutten.  Atopic Dermatitis: Global Epidemiology and Risk Factors , 2015, Annals of Nutrition and Metabolism.

[8]  Z. Vogel,et al.  Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype , 2013, Journal of Neuroimmune Pharmacology.

[9]  S. Takeuchi,et al.  Visual analogue scale: evaluation of the instrument for the assessment of pruritus. , 2012, Acta dermato-venereologica.

[10]  L. Misery,et al.  What is Intrinsic Atopic Dermatitis? , 2011, Clinical reviews in allergy & immunology.

[11]  L. Hynan,et al.  The 5‐D itch scale: a new measure of pruritus , 2010, The British journal of dermatology.

[12]  A. Qureshi,et al.  Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. , 2006, Archives of dermatology.

[13]  G. Cabral,et al.  Cannabinoid receptor expression in immune cells. , 1996, Advances in experimental medicine and biology.